TECHBio-Techne
- Next report
- No date yet
- none in the next 8 weeks
- Price
- $72.86
- +0.08% today · $11.2B cap
Past and upcoming reports
1
| Nov 11, 2026 | Sep 30, 2026 | Time not given | $0.40 | not recorded |
After the report
Nov 11, 2026 report
Bio-Techne ended the reported earnings day essentially unchanged, while valuation and growth metrics remained demanding.
Actual EPS was not captured. Shares closed at $72.79, down 0.04%, with no post-earnings news or company-specific guidance commentary provided.
Reported against expected
Reported EPS is unknown. the pre-print consensus estimate was $0.40, but no actual result or beat/miss can be confirmed.
Guidance
No explicit post-earnings guidance or management commentary was provided. forward EPS growth estimates ranged from 6.9% to 15.0%.
How the stock reacted
Shares finished at $72.79, down $0.03 or 0.04% on 2.61 million shares. event-day reaction data was unavailable.
What changed
Shares slipped 0.04% on the reported earnings day, while actual EPS and company guidance remained uncaptured.
What the price now assumes
The $72.79 price is near the $73 analyst target despite 34.5 forward P/E and 5.33 PEG valuation.
What it means for the business
Keep a cautious bias. upgrade only if the next update confirms EPS growth near 15% without renewed demand deterioration.
The next one to three months, as we saw it then
Better case30%
A favorable next update could support the premium valuation if forward EPS growth approaches the 14.96% estimate and demand improves.
Base case45%
The stock may consolidate near $73 as limited earnings disclosure offsets the 23.01% one-year gain and mixed operating trends.
Worse case25%
A valuation reset is possible if weak growth persists, given 0.2% TTM revenue growth, -15.7% EPS growth, and 5.33 PEG.
If you hold it
Hold unless next-quarter revenue misses guidance materially or customer concentration risk worsens.
If you are watching
Enter only if a company update confirms forward EPS growth near 14.96%. no trade if guidance remains unavailable and valuation stays near 34.5 forward P/E.
Scenario odds are a judgement, not measured.